Phase 3 Study to Evaluate Safety, Immune Response, and Effectiveness of the MTBVAC Vaccine Compared to BCG in Healthy Newborns in Sub-Saharan Africa
Led by Biofabri, S.L · Updated on 2025-02-10
7120
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, immune response, and improved effectiveness of a new live tuberculosis vaccine called MTBVAC in a Phase 3 trial involving HIV-uninfected infants born to both HIV-infected and uninfected mothers. This study compares MTBVAC to the standard BCG vaccine in regions of sub-Saharan Africa with high TB rates. The project builds on partnerships between European and African institutions and aims to enhance laboratory capacity for TB vaccine studies and sample storage to better understand protection mechanisms.
The trial involves two groups one receiving the MTBVAC vaccine and the other receiving the standard BCG vaccine. Both vaccines are given as a single 0.05 mL dose by injection into the left upper arm within seven days of birth. MTBVAC is a genetically modified vaccine designed to include more tuberculosis antigens than BCG. The vaccines are stored and administered under strict conditions and the optimal MTBVAC dose will be selected based on earlier phase studies.
Participants will be followed for a minimum of 24 months up to a maximum of 80 months, with regular monitoring for signs of tuberculosis disease and vaccine safety. Researchers will assess the vaccines ability to prevent TB and record any side effects. The study includes medical evaluations, access to maternal and infant health records, and collection of immunological data to better understand how the vaccine works. The total participation period covers several years to fully evaluate long-term safety and effectiveness.
CONDITIONS
Brief Title
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
Research Team
I
Ingrid Murillo Jelsbak
A
Andrea García Silva
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Male or female newborns within seven days of birth.
Written informed maternal consent including permission to access maternal and infant medical records.
Infant and caregiver available and willing to comply with trial procedures.
Newborns in good health during pregnancy and delivery.
Birth weight of at least 2450 grams.
Apgar score at 5 minutes of 7 or higher.
Maternal HIV test result available within 30 days before or 7 days after delivery, or documented HIV uninfected status.
If mother is HIV infected, she must be on antiretroviral therapy with viral load below 50 copies/mL within six months of labour.
Estimated gestational age of 37 weeks or more.
Mother has not participated in a clinical trial within three months prior to birth.
Mother has never participated in a TB vaccine trial.
Infant not participating in any other clinical trials.
You will not qualify if you...
Receipt of BCG vaccination before enrolment.
Significant antenatal, intrapartum, or postpartum complications affecting newborn health.
Skin condition, bruising, or birthmark at the injection site.
Maternal HIV test result not available.
HIV-exposed newborn's HIV PCR positive or not available.
Maternal history of tuberculosis during pregnancy.
Close or household contact with a TB patient who has not completed treatment.
Clinically suspected neonatal sepsis.
Severe congenital malformations.
History or evidence of systemic disease or illness that may interfere with vaccine safety and immune response evaluation, except clinically insignificant neonatal jaundice.
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Single day
Participants receive a single dose of either the MTBVAC vaccine or the BCG vaccine by intradermal injection in the left deltoid area shortly after birth.
1 vaccination visit (in-person)
Long-term Monitoring
Duration - Minimum of 24 months to a maximum of 80 months
Participants are monitored for safety, immunogenicity, and efficacy outcomes related to tuberculosis over an extended period.
Multiple follow-up visits over several years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Testing a 1-Month Ultra-Short Treatment to Prevent Active Tuberculosis in School Contacts
Comparing 1H3P3 and 3HR Regimens in Adolescents and School Staff
Phase 2b Study Comparing JDB0131 Benzenesulfonate Tablets and Delamanid
in Combination Treatments for Rifampin-Resistant Tuberculosis
Safety and Drug Level Study of Isoniazid Inhalation by Wet Nebulization in Adults with Tuberculosis
Dose Finding and Safety Study of Daily Rifapentine with Isoniazid for Tuberculosis Prevention in Children Under 13 With and Without HIV
Phase 2 Open-label Study of Oral Alpibectir with Ethionamide and with Rifampicin, Pyrazinamide, and Ethambutol in Adults with Newly Diagnosed Drug-Susceptible Pulmonary Tuberculosis
Phase 1 Study of Oral Microgynon and Ganfeborole Interaction in Healthy Non-Childbearing Female Adults Aged 18 to 64 Years
Screening for Tuberculosis in High-Risk Groups Living in Barcelona
Study on Screening for Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients
Comparing Moderate Drinking Advice to Abstention Advice for Adults 50 to 75 Years to Prevent Major Diseases and Death
Supporting and Accelerating Tuberculosis Research Through Assessment of New Point-of-Care Diagnostic Tests
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel.
Stephen M Graham, Tahmeed Ahmed, Farhana Amanullah...
MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies.
Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.
Michele Tameris, Helen Mearns, Adam Penn-Nicholson...